Structure Therapeutics reported Phase 2 results showing its oral GLP‑1 candidate aleniglipron produced substantial, sustained weight loss in a 44‑week study. The company said participants on aleniglipron lost up to 16% of body weight versus placebo and is advancing the program toward Phase 3. The data were disclosed by Structure and summarized in clinical updates circulated March 16–17; analysts described the efficacy as “injectable‑like.” GLP‑1 receptor agonists mimic incretin hormones to reduce appetite and improve glycemic control—a key mechanism for obesity and metabolic disease treatment. Regulatory and commercial trajectories will hinge on larger pivotal trials and tolerability across broader populations. Structure adjusted dosing and step‑up regimens to reduce discontinuations, and management plans Phase‑3 starts in H2. Investors and competitors will watch safety, dose optimization, and how oral candidates stack up versus established injectables from Novo Nordisk and Lilly.